Strategic Highlights and Recent Developments
- Q1 sales of
$30.9 million driven by 27,472 Light Adjustable Lens (LAL) units - 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units
- Robust clinical data presented at the recent
American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustability - Recent regulatory approval in
New Zealand furthering the company’s international footprint and global market opportunity - 2026 sales and gross margin guidance unchanged; operating expense expected to be at high end of previous range reflecting targeted investments in strategic growth initiatives
“We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives,” said
First Quarter Financial Results
In the first quarter of 2026, the company reported sales of
First quarter gross profit margin of 76.1% increased from 74.8% in the prior-year period, primarily driven by a favorable shift in product mix toward LAL sales.
Total operating expenses were
In the first quarter of 2026, the company reported a net loss of
As of
2026 ASCRS Highlights
At the recent ASCRS annual meeting,
2026 Guidance
The company’s 2026 financial guidance is as follows:
- Revenue of
$120 to$135 million , in-line with previous guidance - Gross margin of 70% to 72%, in-line with previous guidance
- Operating expenses expected to be at the high-end of previous
$150 to$160 million range - Non-cash stock-based compensation expense of
$30 to$32 million , in-line with previous guidance
Conference Call
On
About
Forward-Looking Statements
This press release contains forward-looking statements, including: including statements regarding the company’s expectations related to stabilizing business trends; the initial progress from its ongoing commercial initiatives; ongoing refinement of its commercial efforts; continued investments in its team and pipeline; its ability to build momentum across the company; and its ability to reach the full potential of its technology for patients and practices. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended
Investor Relations Contact:
VP, Investor Relations
omoravcevic@rxsight.com
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts) | |||||||
| Three Months Ended | |||||||
| 2026 | 2025 | ||||||
| Sales | $ | 30,893 | $ | 37,895 | |||
| Cost of sales | 7,395 | 9,566 | |||||
| Gross profit | 23,498 | 28,329 | |||||
| Operating expenses: | |||||||
| Selling, general and administrative | 31,855 | 28,636 | |||||
| Research and development | 9,472 | 10,367 | |||||
| Total operating expenses | 41,327 | 39,003 | |||||
| Loss from operations | (17,829 | ) | (10,674 | ) | |||
| Other income (expense), net: | |||||||
| Interest expense | (3 | ) | (6 | ) | |||
| Interest and other income | 1,954 | 2,508 | |||||
| Loss before income taxes | (15,878 | ) | (8,172 | ) | |||
| Income tax expense | 6 | 18 | |||||
| Net loss | $ | (15,884 | ) | $ | (8,190 | ) | |
| Other comprehensive loss | |||||||
| Unrealized loss on short-term investments | (120 | ) | (157 | ) | |||
| Foreign currency translation gain | — | 6 | |||||
| Total other comprehensive loss | (120 | ) | (151 | ) | |||
| Comprehensive loss | $ | (16,004 | ) | $ | (8,341 | ) | |
| Net loss per share: | |||||||
| Basic & diluted | $ | (0.38 | ) | $ | (0.20 | ) | |
| Weighted-average shares used in computing net loss per share: | |||||||
| Attributable to common stock, basic & diluted | 41,306,110 | 40,509,646 | |||||
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) | ||||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 17,573 | $ | 19,949 | ||||
| Short-term investments | 200,307 | 208,179 | ||||||
| Accounts receivable, net | 22,443 | 23,383 | ||||||
| Inventories, net | 34,869 | 31,559 | ||||||
| Prepaid and other current assets | 4,032 | 4,389 | ||||||
| Total current assets | 279,225 | 287,459 | ||||||
| Property and equipment, net | 13,232 | 13,056 | ||||||
| Operating leases right-of-use assets | 9,760 | 9,959 | ||||||
| Restricted cash | 750 | 750 | ||||||
| Other assets | 1,026 | 590 | ||||||
| Total assets | $ | 303,993 | $ | 311,814 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,124 | $ | 5,296 | ||||
| Accrued expenses and other current liabilities | 18,748 | 19,795 | ||||||
| Lease liabilities | 1,504 | 1,162 | ||||||
| Total current liabilities | 27,376 | 26,253 | ||||||
| Long-term lease liabilities | 9,322 | 9,878 | ||||||
| Other long-term liabilities | — | — | ||||||
| Total liabilities | 36,698 | 36,131 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Common stock, | 41 | 41 | ||||||
| Preferred stock, | — | — | ||||||
| Additional paid-in capital | 944,244 | 936,628 | ||||||
| Accumulated other comprehensive (loss) income | (67 | ) | 53 | |||||
| Accumulated deficit | (676,923 | ) | (661,039 | ) | ||||
| Total stockholders' equity | 267,295 | 275,683 | ||||||
| Total liabilities and stockholders' equity | $ | 303,993 | $ | 311,814 | ||||
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in
We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share
Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.
Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:
| Three months ended | ||||||||
| 2026 | 2025 | |||||||
| Common Stock | ||||||||
| Numerator: | ||||||||
| Net loss available to stockholders, basic and diluted | $ | (15,884 | ) | $ | (8,190 | ) | ||
| Add: | ||||||||
| Stock-based compensation | 7,945 | 7,140 | ||||||
| Adjusted net loss available to common stockholders, basic and diluted: | $ | (7,939 | ) | $ | (1,050 | ) | ||
| Denominator: | ||||||||
| Weighted-average shares outstanding, basic and diluted | 41,306,110 | 40,509,646 | ||||||
| Adjusted net loss per share, basic and diluted | $ | (0.19 | ) | $ | (0.03 | ) | ||
